Puma Biotechnology

Puma Biotechnology granted a 7,500-share restricted stock unit award to a new non-executive employee on Dec 2, 2024, under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with vesting conditions tied to continued employment.

Puma Biotechnology (NASDAQ: PBYI) approved a 7,500-share restricted stock unit award for a new non-executive employee under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with one-third vesting on December 1, 2025, and one-sixth every six months thereafter, contingent on continued employment, complying with Nasdaq Listing Rule 5635(c)(4).

Victory Capital Management Inc. increased its stake in Puma Biotechnology by 111.9% in Q3, owning 35,097 shares worth $89,000. Other investors also adjusted their positions, with American Century Companies Inc. raising its stake by 98.5% and Affinity Asset Advisors LLC acquiring a new stake worth $815,000. Puma Biotechnology reported $0.41 EPS for Q3, beating estimates, and analysts forecast 0.29 EPS for the current year. StockNews.com downgraded Puma Biotechnology from a “strong-buy” to a “buy” rating.

A phase 2 study, ALISCATM-Breast1, has begun for HR-positive, HER2-negative metastatic breast cancer patients to evaluate alisertib, an Aurora A kinase inhibitor. The study aims to determine the optimal dose of alisertib plus endocrine therapy, with main goals including objective response rate, duration of response, disease control rate, progression-free survival, and overall survival. Initial data is expected in 2025.

Puma Biotechnology (PBYI) is a strong value stock with a Zacks Rank of #2 (Buy) and an A for Value. PBYI's P/B ratio of 2.17 and P/CF ratio of 4.44 are attractive compared to industry averages, indicating potential undervaluation.

Puma Biotechnology (NASDAQ:PBYI) downgraded from 'strong-buy' to 'buy' by StockNews.com. HC Wainwright maintains 'buy' rating with $7.00 target. PBYI stock opened at $3.00, trading up 3.4%. The company reported $0.41 EPS, beating estimates. Institutional investors increased stakes, with hedge funds owning 61.29% of the stock. Puma Biotechnology focuses on cancer care, offering NERLYNX for HER2-positive breast cancer.

Puma Biotechnology (NASDAQ:PBYI) downgraded from 'strong-buy' to 'buy' by StockNews.com. HC Wainwright maintains 'buy' rating with $7.00 price target. PBYI stock up 3.4% to $3.00, with a trading volume of 538,317 shares. Puma reported $0.41 EPS, surpassing estimates of $0.31, with revenue of $80.50 million. Institutional investors increased stakes in Q3.